

RECEIVED
SEP 05 2002
TECH CENTER 1600/2900

I. IN THE CLAIMS

Please amend the claims to read as follows. A marked-up version of the amended claims follows, beginning on a separate sheet, in accordance with 37 CFR §1.121(c)(1)(ii).

- A' 12. (Amended) The composition of Claim 1 wherein the cyclodextrin compound is selected from the group consisting of α -cyclodextrin, β -cyclodextrin, γ -cyclodextrin, alkylcyclodextrins, hydroxyalkylcyclodextrins, carboxyalkylcyclodextrins and sulfoalkylether cyclodextrins.

II. REMARKS

A. Rejection of Claim 12, Under 35 U.S.C. § 112, Second Paragraph

Claim 12 was rejected under 35 U.S.C. §112, second paragraph as being indefinite because the claim as filed included the phrase "(e.g. methyl- β -cyclodextrin, dimethyl- β -cyclodextrin, diethyl- β -cyclodextrin)", immediately after the term "alkylcyclodextrins". Claim 12 has been amended herein to remove the entire phrase, in order to clarify the language of this particular claim. Applicant, therefore, respectfully requests that the rejection of claim 12 under 35 U.S.C. § 112 be withdrawn, in view of the above-cited amendment.

B. Rejection of Claims 1-30, Under 35 U.S.C. § 103(a), Over Barbachyn *et al* (U.S. 5,688,792) and in View of Bartroli *et al*. (U.S. 5,646, 297)

Claims 1-30 were rejected, under 35 U.S.C. §103(a), as being unpatentable over Barbachyn *et al*. in view of Bartroli *et al*. All of the claims of the present application depend from claim 1, a claim directed to:

"A pharmaceutical composition "for administration to a subject having or at risk of infective disease, the composition comprising an aqueous carrier having in solution therein

- (a) an oxazolidinone antimicrobial drug concentration that is an effective concentration above the solubility of the drug ..., and
- (b) a pharmaceutically acceptable cyclodextrin compound in a concentration sufficient to maintain the drug in solution at such a drug concentration." (Language of claim 1).